Diagnexia and Stratipath Partner to Expand AI-Based Cancer Precision Diagnostics Across the UK and Europe
Diagnexia, and Stratipath AB are pleased to announce a strategic partnership. This collaboration will bring Stratipath Breast, an AI-based prognostic risk profiling tool for invasive breast cancer, to pathology laboratories, hospitals, and healthcare providers across the UK and Europe.
Professor Daniel Hayes Joins Stratipath’s Scientific Advisory Board
Stratipath is proud to announce that globally recognized breast oncologist, Professor Daniel F. Hayes, has joined the company’s Scientific Advisory Board. Professor Hayes will collaborate closely with the board, chaired by Professor Jonas Bergh, to further advance Stratipath’s innovative solutions in breast cancer precision diagnostics.
Unilabs is implementing Stratipath Breast for enhanced breast cancer diagnostics at Capio S:t Göran’s Hospital
Capio St Göran’s Hospital is one of the largest breast cancer clinics in Sweden treating more than 600 breast cancer patients annually. With this new collaboration, Unilabs will use Stratipath Breast on a selected group of these patients.
Stratipath and Roche Join Forces to Help Expand Access to AI-Powered Precision Diagnostics
Stratipath is thrilled to announce a collaboration with Roche, the world’s largest biotechnology company and the global leader in in-vitro diagnostics.
A new validation study on the prognostic performance of Stratipath Breast.
Stratipath is excited to announce the publication of a new validation study on the prognostic performance of Stratipath Breast—the first AI-based CE-marked medical device for risk stratification of breast cancer using routine H&E histopathology images.
Stratipath Breast AI-based risk profiling for breast cancer is now available for clinical use in the UK.
Stratipath Breast, is now officially registered with the Medicines and Healthcare products Regulatory Agency (MHRA). This registration allows healthcare providers across the United Kingdom access to the AI-based prognostic tool for breast cancer risk profiling.
Stratipath is proud to be a part of Proscia’s new partner alliance ”Proscia Ready”
Stratipath is proud to be a part of Proscia’s new partner alliance ”Proscia Ready”.
Stratipath is now a part of Paige AppLab
Stratipath is now a part of Paige AppLab
Stratipath And Proscia Announce Partnership, Paving The Way To Bring Relapse Risk Prediction To More Breast Cancer Patients
Stratipath, a global leader in artificial intelligence (AI)-based precision diagnostic solutions, and Proscia®, a leading provider of digital and computational pathology solutions, have partnered to help oncologists and pathologists determine the most suitable treatment path for more breast cancer patients.
Professor Jonas Bergh, will be leading our scientific advisory board
Stratipath is happy to announce that one of the most prominent breast oncologists, Professor Jonas Bergh, will be leading the company’s scientific advisory board. As Stratipath is entering the clinical phase with its first-in-class, CE-IVD solution for AI-driven risk profiling, Stratipath breast and at the same time ramping up the research and development efforts for future solutions, the scientific advisory board will play a crucial role in the company’s development.